DBV Technologies (NASDAQ:DBVT) Sees Strong Trading Volume – Here’s What Happened

DBV Technologies S.A. (NASDAQ:DBVT) saw strong trading volume on Wednesday . 626,482 shares were traded during mid-day trading, an increase of 118% from the previous session’s volume of 287,370 shares.The stock last traded at $18.56 and had previously closed at $18.16.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Citizens Jmp increased their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, May 1st. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, Guggenheim restated a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a report on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.50.

DBV Technologies Price Performance

The stock has a market cap of $1.13 billion, a PE ratio of -4.28 and a beta of -0.96. The firm’s 50 day moving average price is $20.00 and its two-hundred day moving average price is $19.39.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The business had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $1.11 million. Analysts anticipate that DBV Technologies S.A. will post -0.47 earnings per share for the current year.

Hedge Funds Weigh In On DBV Technologies

A number of large investors have recently modified their holdings of DBVT. GAMMA Investing LLC lifted its position in DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares during the last quarter. Truvestments Capital LLC lifted its position in DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares during the last quarter. Allworth Financial LP bought a new stake in DBV Technologies during the fourth quarter valued at approximately $32,000. Royal Bank of Canada bought a new stake in DBV Technologies during the fourth quarter valued at approximately $34,000. Finally, New York State Common Retirement Fund bought a new stake in DBV Technologies during the third quarter valued at approximately $34,000. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.